Flucelvax 70461-0555
Generic: Influenza A Virus A/georgia/12/2022 Cvr-167 (h1n1) Antigen (mdck Cell Derived, Propiolactone Inactivated), Influenza A Virus A/victoria/800/2024 Cvr-289 (h3n2) Antigen (mdck Cell Derived, Propiolactone Inactivated),influenza B Virus B/singapore/wuh4618/2021 Antigen (mdck Cell Derived, Propiolactone Inactivated)
Product NDC
70461-0555- Manufacturer
- Seqirus Inc.
- Dosage Form
- Injection, Suspension
- Route
- Intramuscular
- Product Type
- Vaccine
- Marketing Start
- July 1, 2025
- Application
- BLA125408
Active Ingredients
| Ingredient | Strength |
|---|---|
| Influenza A Virus A/georgia/12/2022 Cvr-167 (h1n1) Antigen (mdck Cell Derived, Propiolactone Inactivated) | 15 ug/.5mL |
| Influenza A Virus A/victoria/800/2024 Cvr-289 (h3n2) Antigen (mdck Cell Derived, Propiolactone Inactivated) | 15 ug/.5mL |
| Influenza B Virus B/singapore/wuh4618/2021 Antigen (mdck Cell Derived, Propiolactone Inactivated) | 15 ug/.5mL |
Packaging Options(1)
1 VIAL, MULTI-DOSE in 1 CARTON (70461-555-10) / 5 mL in 1 VIAL, MULTI-DOSE (70461-555-11)
External Resources